Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue 7, 2012, Pages 1157-1162

  Charles Schoeman, Christina ^a   Lee, Yuen Yin ^a   Grijalva, Victor ^a   Amjadi, Sogol ^a   FitzGerald, John ^a   Ranganath, Veena K ^a   Taylor, Mihaela ^a   McMahon, Maureen ^a   Paulus, Harold E ^a   Reddy, Srinivasa T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; MYELOPEROXIDASE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN ISOLATION; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ANIMALS; ANTIOXIDANTS; ANTIRHEUMATIC AGENTS; APOLIPOPROTEIN A-I; ARTHRITIS, RHEUMATOID; ARYLDIALKYLPHOSPHATASE; CELL LINE; CHOLESTEROL; FEMALE; HUMANS; JOINTS; LIPOPROTEINS, HDL; MACROPHAGES; MALE; MICE; MIDDLE AGED; PEROXIDASE; REMISSION INDUCTION;

EID: 84862803161     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200493     Document Type: Article

References (31)

1. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006;113:2548-55. (Pubitemid 43948034)
2. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 2003;92(4A):42J-9J.
3. Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50 Suppl:S189-94.
4. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009;119:1135-45.
5. Sattar N, McCarey DW, Capell H, et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63. (Pubitemid 37553561)
6. Del Rincón I, Williams K, Stern MP, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833-40.
7. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32. (Pubitemid 40365093)
8. Charles-Schoeman C, Watanabe J, Lee YY, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009;60:2870-9.
9. Popa C, van Tits LJ, Barrera P, et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:868-72.
10. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-41. (Pubitemid 39572103)
11. Zheng L, Settle M, Brubaker G, et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 2005;280:38-47. (Pubitemid 40164962)
12. Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001;42:1308-17. (Pubitemid 32744255)
13. Charles-Schoeman C, Khanna D, Furst DE, et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007;34:1459-64. (Pubitemid 47067979)
14. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004;109:3215-20.
15. Furlong CE, Richter RJ, Seidel SL, et al. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988;43:230-8.
16. Filippin LI, Vercelino R, Marroni NP, et al. Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol 2008;152:415-22. (Pubitemid 351661493)
17. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402-11. (Pubitemid 40220344)
18. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
19. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5. (Pubitemid 34136564)
20. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
21. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-7. (Pubitemid 350100691)
22. Hazen SL, Hsu FF, Mueller DM, et al. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 1996;98:1283-9. (Pubitemid 26322052)
23. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 2000;28:1717-25. (Pubitemid 30628658)
24. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604. (Pubitemid 37288567)
25. Feijóo M, Túnez I, Tasset I, et al. Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases. Pharmacology 2009;83:211-16.
26. Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 2004;101:13032-7. (Pubitemid 39167578)
27. Shao B, Oda MN, Bergt C, et al. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem 2006;281:9001-4. (Pubitemid 43864611)
28. Wu Z, Wagner MA, Zheng L, et al. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol 2007;14:861-8. (Pubitemid 47373831)
29. Shao B, Cavigiolio G, Brot N, et al. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci USA 2008;105:12224-9.
30. Dessein PH, Norton GR, Woodiwiss AJ, et al. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2007;34:943-51. (Pubitemid 46774836)
31. Vuilleumier N, Bas S, Pagano S, et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2010;62:2640-50.